Skip to main content

Systemic Sclerosis (SSc)

4
Pipeline Programs
7
Companies
7
Clinical Trials
6 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 6 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
TibulizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT06843239Recruiting80Est. Jan 2028
Overland Therapeutics
Overland TherapeuticsChina - Shanghai
1 program
1
OL-CD19-GDTPhase 11 trial
Active Trials
NCT07167537Recruiting44Est. Dec 2028
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
UTAA91 injectionPhase 11 trial
Active Trials
NCT07000682Recruiting24Est. Jan 2040
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
UTAA91 injectionPhase 11 trial
Active Trials
NCT06982534Not Yet Recruiting24Est. Jan 2040
T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
Apollo Neuro DeviceN/A1 trial
Sodium ThiosulfatePHASE_21 trial
Active Trials
NCT06675344Recruiting160Est. Sep 2028
NCT06672822RecruitingEst. May 2029
argenx
argenxBelgium - Zwijnaarde
1 program
Efgartigimod PH20 SCPHASE_21 trial
Active Trials
NCT06655155Recruiting81Est. Sep 2027
Zura Bio
Zura BioLA JOLLA, CA
1 program
TibulizumabPHASE_2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
2031
T-TherapeuticsSodium Thiosulfate
BiocorpTibulizumab
argenxEfgartigimod PH20 SC
Overland TherapeuticsOL-CD19-GDT
BioTherapeutics IncUTAA91 injection
UNION therapeuticsUTAA91 injection
T-TherapeuticsApollo Neuro Device

Clinical Trials (7)

Total enrollment: 413 patients across 7 trials

NCT06672822T-TherapeuticsSodium Thiosulfate

Intralesional Injection of STS in Treatment of Calcinosis

Start: Mar 2025Est. completion: May 2029
Phase 2Recruiting
NCT06843239BiocorpTibulizumab

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Start: Feb 2025Est. completion: Jan 202880 patients
Phase 2Recruiting
NCT06655155argenxEfgartigimod PH20 SC

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Start: Nov 2024Est. completion: Sep 202781 patients
Phase 2Recruiting
NCT07167537Overland TherapeuticsOL-CD19-GDT

A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases

Start: Oct 2025Est. completion: Dec 202844 patients
Phase 1Recruiting
NCT06982534BioTherapeutics IncUTAA91 injection

Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

Start: Jun 2025Est. completion: Jan 204024 patients
Phase 1Not Yet Recruiting
NCT07000682UNION therapeuticsUTAA91 injection

The Clinical Study on the Treatment of SSc With UTAA91 Injection.

Start: May 2025Est. completion: Jan 204024 patients
Phase 1Recruiting
NCT06675344T-TherapeuticsApollo Neuro Device

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

Start: Jan 2025Est. completion: Sep 2028160 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 actively recruiting trials targeting 413 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.